Sugi Predict

Sugi Predict / Compounds / SCHEMBL300278

SCHEMBL300278

SCHEMBL300278

CCC[C@H](N[C@@H](C)C(=O)O)C(=O)OCC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 10/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ LMNA P02545 2/20 0.39
▸ KMT2A Q03164 4/20 0.38
▸ POLB P06746 1/20 0.38
▸ ABCB11 O95342 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ AKR1A1 P14550 1/20 0.38
▸ CHRM3 P20309 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ HTR2C P28335 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ HRH1 P35367 1/20 0.38
▸ DRD3 P35462 1/20 0.38
▸ SLC6A3 Q01959 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC2 Q92769 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ USP2 O75604 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4650239 1.00 ACE (0.49) ACEL3MBTL1LMNAKMT2APOLB
SCHEMBL300279 1.00 ACE (0.49) ACEL3MBTL1LMNAKMT2APOLB
SCHEMBL4400451 1.00 ACE (0.49) ACEL3MBTL1LMNAKMT2APOLB
SCHEMBL13482629 1.00 ACE (0.49) ACEL3MBTL1LMNAKMT2APOLB
SCHEMBL4458272 1.00 ACE (0.49) ACEL3MBTL1LMNAKMT2APOLB
SCHEMBL4458267 1.00 ACE (0.49) ACEL3MBTL1LMNAKMT2APOLB
SCHEMBL1992431 1.00 ACE (0.49) ACEL3MBTL1LMNAKMT2APOLB
SCHEMBL4400447 1.00 ACE (0.49) ACEL3MBTL1LMNAKMT2APOLB
Hydrochloric Acid SCHEMBL5287673 0.98 ACE (0.48) ACEL3MBTL1LMNAKMT2APOLB
Hydrochloric Acid SCHEMBL3536442 0.98 ACE (0.48) ACEL3MBTL1LMNAKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118638065-A Perindopril impurity, preparation method, purification method and composition thereof 南京济群医药科技股份有限公司 2024-09-13 — — CN claimed
CN-113980096-A Process for synthesizing ton-grade perindopril tert-butylamine 绍兴市上虞区武汉理工大学高等研究院 2022-01-28 — — CN claimed
EP-2612851-B1 Process for the preparation of the L-arginine salt of perindopril SERVIER LAB (FR) 2016-07-06 — — EP claimed
US-8865915-B2 Process for the preparation of the L-arginine salt of perindopril LES LABORATOIRES SERVIER (FR) 2014-10-21 — — US claimed
EP-1753720-B1 PROCESS FOR THE PREPARATION OF PERINDOPRIL AND SALTS THEREOF SERVIER S A LAB (FR) 2014-05-07 — — EP claimed
WO-2013102740-A1 METHOD FOR THE PREPARATION OF PERINDOPRIL ARGININE SALT LES LABORATOIRES SERVIER (FR) 2013-07-11 — — WO claimed
US-20130178635-A1 PROCESS FOR THE PREPARATION OF THE L-ARGININE SALT OF PERINDOPRIL LES LABORATOIRES SERVIER (FR) 2013-07-11 — — US claimed
EP-2612851-A1 Process for the preparation of the L-arginine salt of perindopril Les Laboratoires Servier (FR) 2013-07-10 — — EP claimed
EP-1628956-B1 A PROCESS FOR THE PREPARATION OF COMPOUNDS HAVING AN ACE INHIBITORY ACTION LEK PHARMACEUTICALS (SI) 2010-11-17 — — EP claimed
US-7674814-B2 Angiotensin converting enzyme inhibitors; preparation of (2S,3aS,7aS)-1-((2S)-2-(((1S)-1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid; hydrolysis; perindopril erbumine LES LABORATOIRES SERVIER (FR) 2010-03-09 — — US claimed
EP-1751107-A1 PROCESS FOR THE PREPARATION OF PERINDOPRIL Neopharma Limited (GB) 2007-02-14 — — EP claimed
US-20060211867-A1 Process for the preparation of perindopril GLENMARK PHARMACEUTICALS LIMITED (IN) 2006-09-21 — — US claimed
EP-1294689-B1 PREPARATION METHOD OF A NOVEL BETA CRYSTALLINE FORM OF PERINDOPRIL TERT-BUTYLAMINE SALT SERVIER LAB (FR) 2006-04-26 — — EP claimed
EP-1628956-A1 A PROCESS FOR THE PREPARATION OF COMPOUNDS HAVING AN ACE INHIBITORY ACTION LEK Pharmaceuticals D.D. (SI) 2006-03-01 — — EP claimed
WO-2005113500-A1 PROCESS FOR THE PREPARATION OF PERINDOPRIL AND SALTS THEREOF KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) 2005-12-01 — — WO claimed
WO-2005100317-A1 PROCESS FOR THE PREPARATION OF PERINDOPRIL NEOPHARMA LIMITED (GB) 2005-10-27 — — WO claimed
WO-2004101515-A1 A PROCESS FOR THE PREPARATION OF COMPOUNDS HAVING AN ACE INHIBITORY ACTION LEK PHARMACEUTICALS D.D. (CH) 2004-11-25 — — WO claimed
WO-2004099138-A2 PROCESS FOR THE PREPARATION OF PERINDOPRIL CIPLA LIMITED (IN) 2004-11-18 — — WO claimed
EP-0308341-B1 PROCESS FOR THE INDUSTRIAL SYNTHESIS OF PERINDOPRIL AND FOR ITS PRINCIPAL SYNTHESIS INTERMEDIATES ADIR ET COMPAGNIE (FR) 1990-12-12 — — EP claimed
US-4914214-A Process for the industrial synthesis of perindopril ADIR ET CIE (FR) 1990-04-03 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211867-A1 Process for the preparation of perindopril ACE, PRSS1, CYP2S1 ACE 1/4885L3MBTL1 2434/4885LMNA 130/4885
US-20130178635-A1 PROCESS FOR THE PREPARATION OF THE L-ARGININE SALT OF PERINDOPRIL REN, ARG1, ACE ACE 3/4885L3MBTL1 4018/4885LMNA 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.